Advertisement

Topics

Janssen's Sirukumab Faces Difficult US Commercial Path Even If It Clears Approval Hurdles

06:50 EDT 9 Aug 2017 | SCRIP

FDA advisory committee's concerns about a mortality imbalance in Plivensia clinical trials would appear to reduce the odds that the...

      

Related Stories

 

Original Article: Janssen's Sirukumab Faces Difficult US Commercial Path Even If It Clears Approval Hurdles

NEXT ARTICLE

More From BioPortfolio on "Janssen's Sirukumab Faces Difficult US Commercial Path Even If It Clears Approval Hurdles"

Quick Search
Advertisement
 

Relevant Topic

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...